These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 24986993

  • 21. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
    Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
    [Abstract] [Full Text] [Related]

  • 22. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
    Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
    [Abstract] [Full Text] [Related]

  • 23. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression.
    Millar K, Manlhiot C, Yeung RS, Somji Z, McCrindle BW.
    Int J Cardiol; 2012 Jan 12; 154(1):9-13. PubMed ID: 20851480
    [Abstract] [Full Text] [Related]

  • 24. [Current state of diagnosis and treatment of incomplete Kawasaki disease].
    Zhang QY, Du JB.
    Zhonghua Er Ke Za Zhi; 2006 May 12; 44(5):339-41. PubMed ID: 16780709
    [No Abstract] [Full Text] [Related]

  • 25. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J, Su D, Yuan P, Ye B, Qin S, Pang Y.
    Cardiology; 2023 May 12; 148(5):457-468. PubMed ID: 37231847
    [Abstract] [Full Text] [Related]

  • 26. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 12; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 27. Kawasaki disease: part II. Complications and treatment.
    Bayers S, Shulman ST, Paller AS.
    J Am Acad Dermatol; 2013 Oct 12; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [Abstract] [Full Text] [Related]

  • 28. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 12; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 29. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease.
    Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, Innocentini N, Zambetti C, Pancheri JM, Ostrow A, Frazer JR, Sundel RP, Fulton DR, Newburger JW.
    Pediatrics; 2010 Feb 12; 125(2):e234-41. PubMed ID: 20100771
    [Abstract] [Full Text] [Related]

  • 30. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 31. Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.
    Tang Y, Yan W, Sun L, Xu Q, Ding Y, Lv H.
    Clin Rheumatol; 2018 Jul 26; 37(7):1945-1951. PubMed ID: 29330741
    [Abstract] [Full Text] [Related]

  • 32. Giant coronary artery aneurysms in Kawasaki disease: the cost of a missed diagnosis.
    Marta L, Francisco A, Anjos R.
    Cardiol Young; 2013 Aug 26; 23(4):608-9. PubMed ID: 23910022
    [Abstract] [Full Text] [Related]

  • 33. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 26; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 34. High risk of coronary artery aneurysm in Kawasaki disease.
    Mossberg M, Mohammad AJ, Kahn F, Segelmark M, Kahn R.
    Rheumatology (Oxford); 2021 Apr 06; 60(4):1910-1914. PubMed ID: 33150451
    [Abstract] [Full Text] [Related]

  • 35. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Apr 06; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 36. Clinical Presentation and Outcomes of Kawasaki Disease in Children from Latin America: A Multicenter Observational Study from the REKAMLATINA Network.
    Narayan HK, Lizcano A, Lam-Hine T, Ulloa-Gutierrez R, Bainto EV, Garrido-García LM, Estripeaut D, Del Aguila O, Gómez V, Faugier-Fuentes E, Miño-León G, Beltrán S, Cofré F, Chacon-Cruz E, Saltigeral-Simental P, Martínez-Medina L, Dueñas L, Luciani K, Rodríguez-Quiroz FJ, Camacho Moreno G, Viviani T, Alvarez-Olmos MI, Marques HHS, López-Medina E, Pirez MC, Tremoulet AH, Kawasaki Disease REKAMLATINA Network Study Group.
    J Pediatr; 2023 Dec 06; 263():113346. PubMed ID: 36775190
    [Abstract] [Full Text] [Related]

  • 37. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 06; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

  • 38. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 06; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 39. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Apr 06; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 40. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.